Cedars-Sinai Intellectual Property Company helps turn ideas developed by our faculty into viable innovations. Its patent portfolio generates millions of dollars each year to support Cedars-Sinai’s basic and translational biomedical research efforts.

The Cedars-Sinai Accelerator assists growing healthcare startup companies in tailoring their solutions for maximum impact, with mentorship, funding and access to the resources, personnel and network of a world-class academic medical center.

Cedars-Sinai Health Ventures invests in the expansion of companies with viable products and services likely to be adopted by Cedars-Sinai.

CS Lifesciences are your one stop shop consultancy company based in the UK, Ireland and USA that can meet all your Quality, Clinical and Regulatory Needs.

Our knowledge and experience make us uniquely qualified to represent and support Manufacturers of Medical Devices, In Vitro Diagnostics (IVD) and Clinical Diagnostics.

End-to-End support, from development of your product, to establishing your quality management system, managing your clinical trials, regulatory submissions and post market support.  

We understand you have a business to run, and at CS Lifesciences we balance that with delivering your Quality, Clinical and Regulatory requirements. 

Whether navigating the FDA processes, obtaining CE marks or acting as your EU or UK Authorised Representative, CS Lifesciences will take you through the process in a way that minimizes time and resources – while meeting all your needs.

Our hands-on practical approach, is based on years of working with a vast range of different types and sizes of companies, meaning you get the best advice and clearly identified actions which lead to successful approval of your products.

Earlybird was founded in 1997 and we’ve been investing in healthcare since the beginning. Since 2016, Earlybird has had a fund focused specifically on healthcare: Earlybird Health. Our investment approach is broad and global and covers the entire spectrum of healthcare.

We have the experience, network, and capital to help innovative companies grow. Our typical ticket size is up to €15 million, invested over a company’s lifecycle.

We focus on highly differentiated technologies in attractive markets. Whether it's MedTech, Digital Health or Biopharma, we seek out companies that are truly innovating and pushing boundaries in healthcare.

Beyond capital, we bring deep industry knowledge, company-building expertise, and an extensive network that includes strategic partners – helping startups grow.

Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives.

Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most.

Greenberg Traurig (GT) is an international law firm with more than 3,000 attorneys across 51 offices worldwide. Our multidisciplinary team helps clients—from startups to global companies—navigate the complex legal and regulatory challenges that arise at the intersection of science, technology, and health care. We have deep knowledge of the frameworks governing the life sciences and health care sectors, including those set by the FDA and other governmental agencies, and extensive experience managing high-stakes litigation, from single claims to multidistrict matters and mass torts.

GT has a well-established record of developing robust global patent portfolios for medical device and digital health startups that can withstand the scrutiny of diligence and litigation, including some of the most disruptive technologies in MedTech over the last 15 years. In recent years, our team has served as counsel in several landmark transactions, including the #1 and #2 MedTech acquisitions of private companies in 2024, the #1 overall MedTech acquisitions in 2022 and 2024, and the largest MedTech acquisition in the history of Israel. By combining the firm’s collective experience in health care, intellectual property, regulatory, corporate, litigation, and governmental affairs, GT provides clients with innovative, informed, and practical legal strategies to support their business objectives—from discovery through product marketing and beyond.

Mayo Clinic is the largest integrated, not-for-profit medical group practice in the world. The organization is advancing a future in which the best possible care is available to everyone, including expanded care at home. Its relentless research leads to earlier diagnoses and new cures, inspiring hope for patients around the globe.

Mayo Clinic’s multidisciplinary experts collaborate to solve the most complex and unmet patient needs, driving innovations that power new technologies and transform how healthcare is delivered worldwide.

MedtechWOMEN, is a nonprofit organization dedicated to advancing women leaders across the medical technology industry. Through high-impact events, thought leadership programs, and an engaged community, MedtechWOMEN brings together executives, innovators, and investors who are shaping the future of healthcare. Its flagship annual conference, MedtechVISION, along with regional networking events and leadership initiatives, fosters connection, visibility, and inspiration among women driving innovation in medtech.

Helping medical device Sponsors improve healthcare since 1967, NAMSA is the world’s leading MedTech Contract Research Organization (CRO) offering global end-to-end development services. Driven by its global regulatory expertise and in-depth therapeutic knowledge, NAMSA is dedicated to accelerating medical device product development, offering only the most proven solutions to move clients’ products through the development life cycle efficiently and cost-effectively. From medical device testing; regulatory, reimbursement and quality consulting; and clinical research services; NAMSA is the industry’s premier, trusted partner for successful development and commercialization outcomes.

We are NLC Health Ventures, a world-leading healthtech venture builder and early-stage investor. Our purpose is to bring science to life by bridging the gap between scientific discoveries and market-ready solutions that transform patients’ lives.

Innovative medical technologies change lives- but only when patients can access them.

Too often, breakthrough innovations stall due to unclear reimbursement pathways and misaligned stakeholder expectations. Without early, deliberate access strategy, adoption is delayed and patient access is at risk. This is where PRIA comes in….

PRIA Healthcare partners with MedTech innovators to translate breakthrough ideas into reimbursed, scalable care. Founded more than 14 years ago in patient access operational support services, PRIA began by helping facilities and providers through prior authorization and appeals management, for novel technologies, ultimately enabling access for more than 40,000 patients.

Today, PRIA is a full-spectrum partner across reimbursement, market access, and regulatory strategy, supporting companies from early concept through commercialization. Our integrated capabilities – spanning strategic reimbursement, health economics, market access strategy, patient access, payer engagement, regulatory, and quality – are designed to connect evidence, policy, and provider economics, accelerating the adoption of healthcare innovation.

PRIA helps ensure that innovation doesn’t stall at approval- but reaches providers, scales in practice, and ultimately reaches patients.

Advancing Innovation. Unlocking Access. Delivering Impact.

RBrooks Group works exclusively in the Med-Tech industry to source, assess and place top talent in the United States and Europe. Roger Brooks and his team have over 80 years of combined experience assisting early stage and established medical device organizations identify and hire the best C-Suite, board member and vice president executives. We pride ourselves on our reputation and strive to be the most highly regarded executive search firm in the medical device industry

Founded in 1992, The Mullings Group went all in on medtech, healthtech, and life sciences because we saw where the future was headed: people living longer, wanting to live healthier, and technology always seeking higher ground. Since then, we’ve completed over 9,000 successful placements across 900+ companies globally, with a search team that has over 100 years of combine tenure at TMG.

We deliver outcomes across three core areas: executive search, media & marketing, and advisory. Our consultative approach to search identifies and secures the right people at the right time, from individual contributors to C-suite and board roles, utilizing our proprietary tools and trademarked strategies aligned with your organization’s goals. Our advisory services support client-partners on organizational development, succession planning, and strategic initiatives that align people, story, and strategy.

As the only search firm in the world with a full media & marketing arm, we understand how critical it is to tell our clients’ stories at scale. Through Dragonfly, A TMG Company, our 9x award-winning media team develops hiring brands, thought leadership, and positioning strategies that attract talent, capital, and market attention.

With over 200,000 followers on LinkedIn, we’ve established ourselves as the trusted voice and partner in the industry.

Headquartered in Delray Beach, FL, with offices across the U.S., Canada, the UK, Israel, and APAC, we continue to expand alongside the companies driving innovation in medtech and emerging high-tech industries.

TVM Capital Life Science (“TVM”) is a leading international venture capital firm focused on investing in life science innovations.  The company has a highly experienced transatlantic investment team and approximately $900 million under management. TVM’s portfolio focuses on therapeutics and medical technologies from North America and the EU that represent differentiated first-in-class or best-in-class assets with the potential to transform standard of care. 

TVM pursues a unique two-pronged strategy, financing innovative early-stage therapeutics through a single asset company approach (Project-Focused Company, PFC) that leverages the firm’s strategic relationship with global pharmaceutical firm, Eli Lilly and Company. TVM also invests in differentiated commercial-stage medical technologies and late clinical-stage therapeutics. 

With its late-stage investments, TVM focuses on differentiated medical technologies with commercial proof-of-concept as well as late-stage therapeutics expected to quickly reach major development or regulatory milestones. This strategy has been validated through a number of companies in both Fund I and II and the Colucid Pharmaceuticals exit.  

The TVM investment team has worked together for over a decade to effectively utilize this innovative approach to maximize returns for investors and finance new therapies and technologies to meaningfully improve patient lives.